Login to Your Account



Aastrom Launches Landmark Phase III Trial of Ixmyelocel-T

By Marie Powers
Staff Writer

Friday, March 2, 2012
Regenerative medicine pioneer Aastrom Biosciences Inc. enrolled the first patient in its Phase III REVIVE trial assessing the efficacy and safety of ixmyelocel-T in critical limb ischemia (CLI). The primary endpoint of the trial will be amputation-free survival at 12 months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription